中文字幕一区二区三区四区,娇妻极致高潮h,96亚洲精品久久久

新聞發(fā)布 | Medix Biochemica收購myPOLS Biotec以擴(kuò)充其分子診斷原料產(chǎn)品線

? Medix Biochemica全資收購了德國創(chuàng)新型高品質(zhì)分子診斷原料生產(chǎn)商myPOLS Biotec GmbH。

Medix Biochemica has acquired 100 percent of the shares of myPOLS Biotec GmbH, a German manufacturer of innovative and high-quality raw materials in molecular diagnostics.

? 通過收購myPOLS Biotec，Medix Biochemica全球領(lǐng)先的體外診斷原料產(chǎn)品線得到了補(bǔ)充，并擴(kuò)展到分子診斷原料領(lǐng)域。

The acquisition of myPOLS Biotec complements Medix Biochemica's leading portfolio of IVD raw materials and expands its reagent offerings for molecular diagnostics.

? 本次并購使客戶可以從分子診斷相關(guān)領(lǐng)域更強(qiáng)的科技專長獲益，并進(jìn)一步加強(qiáng)公司的全球網(wǎng)絡(luò)。

This acquisition enables customers to benefit from even stronger scientific and technological expertise in molecular diagnostics, and further strengthens the company's global presence.

? 現(xiàn)在您可以從Medix Biochemica的全球銷售網(wǎng)絡(luò)獲得所有myPOLS Biotec相關(guān)產(chǎn)品。

The full myPOLS Biotec product portfolio will now be available through Medix Biochemica's global sales network.

2022年2月1日，芬蘭埃斯波 – 體外診斷關(guān)鍵原料全球領(lǐng)先供應(yīng)商Medix Biochemica全資收購了myPOLS Biotec GmbH (“myPOLS Biotec”)。通過此次并購，Medix Biochemica拓展了其分子診斷領(lǐng)域的原料產(chǎn)品線，補(bǔ)強(qiáng)了其在該領(lǐng)域的技術(shù)能力，并加強(qiáng)了其在西歐的網(wǎng)絡(luò)。MyPOLS Biotec將成為Medix Biochemica新成立的分子診斷原料業(yè)務(wù)的重要組成部分，其卓越的運(yùn)營將保留在德國康斯坦茨繼續(xù)進(jìn)行。本次交易完成后， MyPOLS Biotec的所有創(chuàng)始人將繼續(xù)參與相關(guān)業(yè)務(wù)，并與在康斯坦茨的所有同事一起繼續(xù)致力于持續(xù)創(chuàng)新和分子診斷原料業(yè)務(wù)的增長。

Espoo, 1 February 2022 - Medix Biochemica, a global leader in critical IVD raw materials, has acquired 100 percent of the shares of myPOLS Biotec GmbH ("myPOLS Biotec"). As a result of the acquisition, Medix Biochemica broadens its portfolio of molecular diagnostic raw materials for the in vitro diagnostics ("IVD") industry, complements its scientific expertise and strengthens its local presence in Western Europe. myPOLS Biotec will form a significant part of the newly established Molecular Diagnostics Business Unit within Medix Biochemica Group, and its high-quality operations will continue in Konstanz, Germany. All founders of myPOLS Biotec will remain involved in the business following the transaction with ongoing commitment to innovation and growth of the molecular diagnostics reagents business together with the site in Konstanz.

“作為獨(dú)立原料供應(yīng)商，此次并購是我們實(shí)現(xiàn)成為體外診斷行業(yè)首選合作伙伴這一愿景的一大步。分子診斷原料于我們而言是關(guān)鍵戰(zhàn)略性領(lǐng)域，此次并購將進(jìn)一步加速M(fèi)edix Biochemica在此領(lǐng)域的增長。myPOLS Biotec產(chǎn)品線齊全，且有很多獨(dú)特且創(chuàng)新的分子診斷相關(guān)原料，這補(bǔ)充了Medix Biochemica現(xiàn)有產(chǎn)品線?；趍yPOLS的技術(shù)，我們可以幫助客戶縮短其試劑盒開發(fā)所需時間、降低復(fù)雜性、可以對粗制樣本直接進(jìn)行分子檢測而無需抽提、并為通過定制開發(fā)為合作伙伴的試劑盒開發(fā)提供更高的靈活性。很激動我們有機(jī)會為全球合作伙伴提供這些分子診斷原料”，Medix Biochemica首席執(zhí)行官Steve Ferguson說。

"This acquisition is a great step towards our vision to be the first-choice, independent raw material partner for the IVD industry, and it further accelerates Medix Biochemica's growth in molecular diagnostics reagents business which is a key strategic expansion area for us. The broad portfolio of myPOLS Biotec, including unique and innovative molecular diagnostics reagents, complements Medix Biochemica's existing molecular diagnostics offering. With myPOLS technology, we enable customers to shorten their assay development time and complexity, perform molecular testing directly from crude samples and offer more flexibility to assay development by partnering in custom development. We are excited about the opportunity to offer these molecular diagnostics products to our global customer base," says Steve Ferguson, CEO of Medix Biochemica.

“對于加入Medix Biochemica集團(tuán)我們很興奮”，myPOLS Biotec首席執(zhí)行官Ramon Kranaste說道，“我們期待為Medix Biochemica的強(qiáng)勁增長做出貢獻(xiàn)，我們也很感謝Medix Biochemica對于產(chǎn)品質(zhì)量和研發(fā)的高度重視。myPOLS團(tuán)隊(duì)極強(qiáng)的科研能力、包括其全球最佳的DNA聚合酶，將有力地支持Medix Biochemica實(shí)現(xiàn)其長期愿景以及專注于滿足體外診斷客戶的需求”。

"We are thrilled to join Medix Biochemica Group," says Dr. Ramon Kranaster, CEO of myPOLS Biotec. "We are looking forward to contributing to the strong growth of Medix Biochemica and we appreciate its strong focus on quality and R&D. The high scientific competence of the myPOLS team including best-in-class DNA polymerases, supports Medix Biochemica's long term vision and focus on IVD customers' needs."

關(guān)于myPOLS

myPOLS Biotec是一個創(chuàng)新型生物技術(shù)公司，坐落于德國康斯坦茨，以液體或凍干粉形式為體外診斷和科研領(lǐng)域提供最佳的DNA聚合酶、反應(yīng)預(yù)混液、DNA聚合酶相關(guān)試劑盒及試劑。2014年，公司由康斯坦茨大學(xué)的科學(xué)家創(chuàng)建，并于隨后獨(dú)立運(yùn)營，專注于為分子診斷領(lǐng)域開發(fā)高品質(zhì)試劑以及原料，為PCR、CRISPR、NGS、等溫擴(kuò)增、各種高難度單核苷酸多態(tài)性檢測等不同應(yīng)用提供卓越的定制化DNA聚合酶。2019年4月，myPOLS Biotec通過了ISO 13485:2016認(rèn)證，其產(chǎn)品和服務(wù)得到了世界頂級IVD公司、實(shí)驗(yàn)室、研發(fā)機(jī)構(gòu)及制藥公司的廣泛認(rèn)可。

myPOLS Biotec is an innovative biotechnology company based in Konstanz, Germany, offering best-in-class DNA polymerases, master mixes, DNA polymerase-based assays and reagents in both liquid and lyophilized format for IVD and research use. Founded in 2014, myPOLS Biotec started as a spin-off by scientists from the University of Konstanz, developing high-quality reagents and raw materials for molecular diagnostics by excelling in tailoring DNA polymerases for various applications, such as PCR, CRISPR, NGS and isothermal, and robust SNP detection. Since April 2019, myPOLS Biotec has been certified according to ISO 13485:2016 and its products and services are successfully deployed by leading in vitro diagnostics companies worldwide, as well as laboratories, research organisations, and pharmaceutical companies.

本次交易完成后，所有的MyPOLS Biotec創(chuàng)始人將繼續(xù)參與相關(guān)業(yè)務(wù)。Ramon Kranaster和Simone Marx博士將在分子診斷原料業(yè)務(wù)部門繼續(xù)擔(dān)任重要職位，Andreas Marx博士/教授也將作為高級顧問繼續(xù)服務(wù)。

All founders of myPOLS Biotec will remain involved in the business following the acquisition with Dr. Ramon Kranaster and Simone Marx having key operational roles in the Molecular Diagnostics Business Unit and Prof. Dr. Andreas Marx continuing as a Senior Advisor.

關(guān)于Medix Biochemica

Medix Biochemica集團(tuán)是體外診斷行業(yè)全球領(lǐng)先的關(guān)鍵原料供應(yīng)商。我們的使命是幫助IVD合作伙伴為全球億萬患者提供精準(zhǔn)的診斷結(jié)果。與Medix Biochemica合作，體外診斷試劑生產(chǎn)商可以縮短其產(chǎn)品上市所需時間，這基于我們行業(yè)領(lǐng)先的技術(shù)和體系，可以提高效率，并使其試劑質(zhì)量更可靠。這一切的基石是我們對技術(shù)深刻的理解、極為豐富且高度相關(guān)的產(chǎn)品線、以及對質(zhì)量的不懈追求。Medix Biochemica在全球有超過240名專業(yè)的員工，總部位于芬蘭，通過在亞洲、美國、和歐洲的本地團(tuán)隊(duì)，我們?yōu)槿蚩蛻籼峁┓?wù)。

Medix Biochemica Group are a global, market-leading supplier of critical raw materials to the in vitro diagnostics (IVD) industry. Our mission is to enable IVD customers to deliver accurate results to billions of patients worldwide. By working in partnership with Medix Biochemica, IVD manufacturers can reduce their time to market through our industry-leading expertise which increases efficiencies and builds quality into their tests. We achieve this through our deep scientific know-how combined with the broadest and most relevant raw material portfolio and our relentless focus on quality. Medix Biochemica Group employs more than 240 professionals worldwide. With headquarters in Finland, we serve our worldwide customers through our local teams in the US, Europe, and Asia. www.medixbiochemica.com

以己及人、銳意進(jìn)取、言出必踐

We Care. We Dare. We Deliver.

如需更多信息，請聯(lián)系:

For more information:

Medix Biochemica中國商務(wù)團(tuán)隊(duì)

Commercial Team of Medix Biochemica China

Tel +86 21 6811 9180, 6811 9181, 6811 9105

Email: medixchina@medixbiochemica.com